His chief scientific accomplishments include the identification of the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes, leading a pioneering effort in large-scale systematic cancer genomics and the identification the BRAF mutations in melanoma, ERBB2 mutations in non-small cell lung cancer and multiple new cancer genes in renal cell carcinoma. He has published over 182 papers in peer-reviewed journals.

Dr. Futreal applies his knowledge of cancer genomics to improve both short-term and long-term patient outcomes extending to cancer survivorship. He is a platform leader for genomics and informatics for the Moonshot initiative.

ne of the principal leaders of the Human Genome Project, directing the largest center in the international project. He has developed many of the key concepts, tools and information resources in modern genomics, propelling a revolution in our understanding of inherited disease and cancer, genetic regulation and evolution. The recipient of numerous awards, he was elected a member of the US National Academy of Sciences and Institute of Medicine.

Dr. Lander was appointed by President Obama to co-chair the President’s Council of Advisors on Science and Technology, which advises the White House on matters including health, advanced manufacturing, energy policy, information technology, nanotechnology and national security. Dr. Lander earned his BA from Princeton (1978) and his PhD from Oxford (1981) as a Rhodes Scholar. He teaches on the faculty of MIT and the Harvard Medical School.